regulatory status comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved in the US, EU and Australia | Sale and import restricted; no licensed product |
| Typical test matrices | Urine, serum, seized powder | Urinary detection window is short |
| Primary identification method | LC-MS/MS against a reference standard | High-resolution mass used for confirmation |
| Data sources in the literature | Small trials, case reports, pharmacovigilance | No registrational trial dataset exists |
| Common marketing names | Melanotan 2, MT-II, MT-2 | Label content may not match declared peptide |
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Peukert wrote that the Holocaust would never had happened without the shift from the thinking of scientists from concern with the body of the individual to concern with the body of the collective volkskörper, the tendency to break society into those of "value" and those of "lesser value" and with seeing the solution to social problems as eliminating the genes of those of "lesser value". Peukert wrote that the fascination with pseudo-scientific racial theories and eugenics were common to all of the West, but it was the specific conditions in Germany which allowed the National Socialists to come to power 1933 that led to the "Final Solution to the Jewish Question". Peukert wrote: "The 'death of God' in the nineteenth century gave science dominion over life. For each individual human being, however, the borderline experience of death rebuts this claim to dominion. Science therefore sought its salvation in the specious immortality of the racial volkskörper, for the sake of which real-and hence more imperfect-life could be sacrificed. Thus the instigators of the "Final Solution" finally achieved dominion over death". Through Peukert was on the left, the conservative American intellectual M.D. Aeschliman praised Peukert's essay in The National Review as "important" and "haunting". He wrote that after the war that scientists who had provided the intellectual justification for the "Final Solution" were not prosecuted and a massive effort to block the memory of their actions started which largely prevented any discussion of the subject in the 1950s-1960s.
The introductions of Mia and Chloe helped further exploration of Ari's fictional backstory. It emerges that after their baby son died, Ari's grief caused him to self-destruct and he was later sent to prison for 10 years. Mia then chose to move away with Chloe, who lost the only father figure she had ever known. Ari is surprised when Chloe turns up in the Bay to see him, and he soon learns that Mia lied to Chloe about why he left them, saying that he did not want to be in their lives anymore. Kipa-Williams explained: "Just before her 10th birthday, Ari ended up getting arrested armed robbery and he went to jail. This left Chloe feeling very confused and hurt as to why he never came back home." The actor also said that Ari has mixed emotions about Chloe's arrival, as he knows that Mia will be close behind her and he is unsure about facing his past so soon. Mia turns up at Ari's door just as he is telling Mac about their history. Kipa Williams branded the exes "star-crossed lovers" and said they had a long history together. Ari knows that things were left unresolved between them and Kipa Williams believed that Ari never stopped loving Mia. After he breaks up with Mac, Ari has an awkward meeting with Mia in the gym. Kipa-Williams explained: "Ari doesn't actually tell Mia he's broken up with Mac, so Mia remains guarded and communicates with him like he's still in a relationship." While Kipa-Williams was disappointed about the end of Ari and Mac's relationship, he relished the opportunity to explore his character's background further with Mia and Chloe.
== Chemistry == Do6a is the most abundant peptide in D. occidentalis venom with an EC50 of 113 nM which is much lower than that of other peptides in the same venom (for example, Do10a has an EC50 of 75 μM). The sequence of Do6a shares similarities in both amino acid composition and length to a known endogenous pain signaling peptide; Vulnusin. Vulnusin, which is present in Drosophila larvae, signals the larvae to initiate puncture-induced rolling as a defense strategy for moving away from parasitoid wasps. Compared to Do6a, Vulnusin has a significantly lower EC50, making it more potent. Nevertheless, there are speculations that velvet ants evolved venom peptides similar to vulnusin in order to target the same ion channel complex. Despite being the most potent and concentrated peptide in red velvet ant venom, Do6a alone does not appear to give rise to any considerable nocifensive responses in mice, such as paw licking. Even when administered at concentrations up to 10,000 higher than the EC50 for larval nociceptor activation, its effects in mice remain negligible. This indicates that the mode of action underlying Do6a-induced nociception differs between mammals and insects.
Sources: en.wikipedia.org
March 31, 2004: The Ministry Delegate for Parity and Professional Equality gains its autonomy. May 26, 2004: Law concerning divorce; the protection of the spouse victim of violence is taken into account. July 1, 2004: Decree concerning the conditions for performing voluntary terminations of pregnancy outside healthcare establishments and amending the Public Health Code (second part: Regulatory part). August 6, 2004: Law concerning bioethics. November 24, 2004: Plan to combat violence against women. November 24, 2004: Ordinance concerning the legislative part of the Code on the Entry and Residence of Foreigners and the Right of Asylum. March 23, 2006: Law concerning equal pay between women and men. April 5, 2006: Law on strengthening the prevention and repression of violence within couples or against minors. December 30, 2004: Law establishing the French Equal Opportunities and Anti-Discrimination Commission (HALDE). March 17, 2005: Decree concerning the family reunification of foreigners for the application of Book IV of the Code on the Entry and Residence of Foreigners and the Right of Asylum. April 2, 2005: Orientation and Program Law for the Future of the School, which emphasizes that it must "promote coeducation and equality between men and women." June 2, 2005: Creation of the Ministry Delegate for Social Cohesion and Parity. July 4, 2005: Ordinance reforming filiation. August 2, 2005: Law in favor of small and medium-sized enterprises; it notably includes provisions concerning the status of the collaborating spouse.
===== Uruguay ===== In December 2024, Lula visited Uruguay to attend a Mercosur summit that culminated in the signing of the EU–Mercosur Association Agreement. He also met with former Uruguayan former president José Mujica, whom he decorated with the Order of the Southern Cross, Brazil's highest award, and president-elect Yamandú Orsi.
== Other related drugs == 5-Chloro-AMT (PAL-542) – serotonin–dopamine releasing agent (SDRA), serotonin receptor agonist, and monoamine oxidase A (MAO-A) inhibitor 5-Fluoro-AMT (PAL-212; PAL-544) – serotonin–norepinephrine–dopamine releasing agent (SNDRA), serotonin receptor agonist, and monoamine oxidase A (MAO-A) inhibitor CPI-CG-8 – serotonin 5-HT2C receptor agonist Methocinnamox (MCAM) – long-lasting irreversible μ-opioid receptor antagonist Methoclocinnamox (MCCAM; NIH-10420) – long-lasting irreversible μ-opioid receptor partial agonist Oxa-noribogaine – atypical κ-opioid receptor agonist (noribogaine analogue) SR-17018 (SR17018; SR-17; SR17; SR) – μ-opioid receptor biased agonist
=== Structure === Muscimol was first isolated from Amanita pantherina by Onda in 1964, and thought to be an amino acid or peptide. Structure was then elucidated by Takemoto, Eugster, and Bowden. Muscimol is a semi-rigid isoxazole containing both alcohol and aminomethyl substituents. Muscimol is commonly portrayed as a tautomer, where it adopts an amide-like configuration. It is also commonly shown as a zwitterion.
Sources: en.wikipedia.org
=== Reaction pathways === Diterpenes are commonly synthesized from the precursor molecule geranylgeranyl pyrophosphate (GGPP). GGPP's hydrocarbon backbone can be rearranged into different structures that may be further rearranged or added to in order to create precursors for different families of diterpenoid compounds. This precursor molecule may be synthesized through the mevalonic acid pathway or the deoxyxylulose pathway. These pathways produce isopentenyl pyrophosphate, which can be rearranged into GGPP. The cyclization of GGPP and the subsequent reorganizations into different precursors is controlled by a large family of enzymes known as diterpene syntheses (diTPS). To synthesize sugiol a plant must first synthesize GGPP through either of the previously mentioned pathways, (mevalonic acid or the deoxyxylulose pathway), then rearrange GGPP into the molecule mitiradiene. After formation of an intermediate compound abietatriene, a cytochrome P450 enzyme can then attach an oxygen molecule to the intermediate. This produces ferruginol, which can then be modified to sugiol by sugiol synthase. Sugiol may then be formed through the modification of ferruginol according to the following reaction driven by the enzyme sugiol synthase.
==== Negative selection ==== Negative selection removes thymocytes that are capable of strongly binding with "self" MHC molecules. Thymocytes that survive positive selection migrate towards the boundary of the cortex and medulla in the thymus. While in the medulla, they are again presented with a self-antigen presented on the MHC complex of medullary thymic epithelial cells (mTECs). mTECs must be Autoimmune regulator positive (AIRE+) to properly express tissue-specific antigens on their MHC class I peptides. Some mTECs are phagocytosed by thymic dendritic cells; this makes them AIRE− antigen presenting cells (APCs), allowing for presentation of self-antigens on MHC class II molecules (positively selected CD4+ cells must interact with these MHC class II molecules, thus APCs, which possess MHC class II, must be present for CD4+ T-cell negative selection). Thymocytes that interact too strongly with the self-antigen receive an apoptotic signal that leads to cell death. However, some of these cells are selected to become Treg cells. The remaining cells exit the thymus as mature naive T cells, also known as recent thymic emigrants. This process is an important component of central tolerance and serves to prevent the formation of self-reactive T cells that are capable of inducing autoimmune diseases in the host.
== History == The solution takes the name from British chemist Henry Drysdale Dakin (1880–1952) who developed it in 1916, during World War I, while he was stationed at a field hospital in Compiègne. He worked there in collaboration with French physician Alexis Carrel, and the particular use they made of the solution is known as the Carrel–Dakin method for wound treatment. Sodium hypochlorite solution had been developed as a bleaching agent around 1820 by the French chemist Antoine Labarraque, as a cheaper substitute for Claude Berthollet's potassium hypochlorite solution, produced as Eau de Javel since the late 18th century. Around that time, he also discovered the disinfectant properties of his Eau de Labarraque, which was quickly adopted for that purpose. His work greatly improved medical practice, public health, and the sanitary conditions in hospitals, slaughterhouses, and all industries dealing with animal products. However, those products were too concentrated and alkaline for use on wounds, as they strongly irritated healthy tissues. Almost a century later Carrel and Dakin observed that few doctors at the time practiced asepsis, and moreover there were no studies of the effectiveness of various antiseptics for wounds. They set out to look for a substance that did not irritate skin, yet had sufficient bactericidal power. Dakin tested more than 200 substances, measuring their action on tissues and bacteria.
== Consumption == In 2021, Koreans collectively consumed 1,965,000 tons of Kimchi, with average Korean consuming 88.3 grams of Kimchi daily. This average has been steadily declining from 109.9 grams per day in 2010, marking a 19.6% decrease. Males tend to consume more Kimchi than females, with an average of 106.6 grams compared to 70.0 grams.
These were deemed to be a hazard to the ecosystem because they prevented sunlight and oxygen from reaching the water. The government eventually prohibited this practice which led to a disposal problem for producers of other dairy products. Their first solution was to use it as a cheap filler in the production of ice cream. Whey eventually found its way into innumerable other products as a filler and ultimately into a number of health food products where it remains a popular supplement.
Sources: en.wikipedia.org
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.
Reversed-phase LC-MS/MS is the usual approach for both identification and quantitation. High-resolution mass spectrometry and peptide mapping serve as confirmatory methods. Immunoassays are rarely used alone because of cross-reactivity.
Published testing of seized and purchased samples frequently reports discrepancies between declared and measured peptide content. Counter-ion content and residual solvents add further variation. Independent analysis is the only way to confirm composition.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.